Sotera Health Reports Q3 2026 Growth Driven by Sterigenics and Nelson Labs
Sotera Health (SHC) reported third-quarter 2026 results characterized by steady revenue growth and margin expansion. Total revenue reached $325 million, a 4.4% increase compared to the previous year. The company's Sterigenics segment saw strong performance with an 8.2% constant currency revenue increase, while Nelson Labs also grew by 9.2%. These gains helped drive Adjusted EBITDA to $171 million, representing a 3.9% increase. Despite the solid quarterly performance, management issued cautious commentary regarding the medical device market environment. CEO Alton E. Shader noted recent softness in demand, particularly among European customers, which may impact sequential growth for Sterigenics in the fourth quarter. Additionally, foreign exchange is expected to act as a headwind in Q4. Nevertheless, Sotera Health reaffirmed its full-year 2026 guidance for revenue and Adjusted EPS.
Coverage
- Cresco Labs reports Q3 results
- Teradata forecasts FY 2026 non-GAAP EPS of $2.86 to $2.90 while reaffirming 2% to 4% total ARR guidance
- Viemed Healthcare Reports Q3 2026 Growth Driven by Sleep Therapy and Maternal Health
- Sotera Health Reports Q3 2026 Growth Driven by Sterigenics and Nelson Labs
- Sotera Health Reaffirms 2026 Outlook Amidst European Medical Device Market Softness